Portraits of breast cancer progression

被引:24
作者
Dalgin, Gul S.
Alexe, Gabriela
Scanfeld, Daniel
Tamayo, Pablo
Mesirov, Jill P.
Ganesan, Shridar
DeLisi, Charles
Bhanot, Gyan [1 ]
机构
[1] Simons Ctr Syst Biol, Inst Adv Study, Princeton, NJ 08540 USA
[2] Canc Inst New Jersey, New Brunswick, NJ 08903 USA
[3] Boston Univ, Ctr Adv Genom Technol, Dept Biomed Engn, Boston, MA 02215 USA
[4] Rutgers State Univ, BioMaPS Inst, Piscataway, NJ 08854 USA
[5] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA
[6] Boston Univ, Mol Bio Cell Bio & Biochem Prog, Boston, MA 02215 USA
[7] MIT, Broad Inst, Cambridge, MA 02142 USA
[8] Harvard Univ, Cambridge, MA 02142 USA
关键词
D O I
10.1186/1471-2105-8-291
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Clustering analysis of microarray data is often criticized for giving ambiguous results because of sensitivity to data perturbation or clustering techniques used. In this paper, we describe a new method based on principal component analysis and ensemble consensus clustering that avoids these problems. Results: We illustrate the method on a public microarray dataset from 36 breast cancer patients of whom 31 were diagnosed with at least two of three pathological stages of disease ( atypical ductal hyperplasia (ADH), ductal carcinoma in situ ( DCIS) and invasive ductal carcinoma (IDC). Our method identifies an optimum set of genes and divides the samples into stable clusters which correlate with clinical classification into Luminal, Basal-like and Her2+ subtypes. Our analysis reveals a hierarchical portrait of breast cancer progression and identifies genes and pathways for each stage, grade and subtype. An intriguing observation is that the disease phenotype is distinguishable in ADH and progresses along distinct pathways for each subtype. The genetic signature for disease heterogeneity across subtypes is greater than the heterogeneity of progression from DCIS to IDC within a subtype, suggesting that the disease subtypes have distinct progression pathways. Our method identifies six disease subtype and one normal clusters. The first split separates the normal samples from the cancer samples. Next, the cancer cluster splits into low grade ( pathological grades 1 and 2) and high grade ( pathological grades 2 and 3) while the normal cluster is unchanged. Further, the low grade cluster splits into two subclusters and the high grade cluster into four. The final six disease clusters are mapped into one Luminal A, three Luminal B, one Basal-like and one Her2+. Conclusion: We confirm that the cancer phenotype can be identified in early stage because the genes altered in this stage progressively alter further as the disease progresses through DCIS into IDC. We identify six subtypes of disease which have distinct genetic signatures and remain separated in the clustering hierarchy. Our findings suggest that the heterogeneity of disease across subtypes is higher than the heterogeneity of the disease progression within a subtype, indicating that the subtypes are in fact distinct diseases.
引用
收藏
页数:16
相关论文
共 33 条
  • [1] Alexe G, 2006, CANCER INFORM, V2, P243
  • [2] ALEXE G, 2007, IN PRESS HIGH EXPRES
  • [3] CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING
    BENJAMINI, Y
    HOCHBERG, Y
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) : 289 - 300
  • [4] Inflammation - A combined effort
    Bussell, K
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (01) : 4 - 4
  • [5] CHEN CH, 1999, P 5 ACM SIGKDD INT C
  • [6] MAXIMUM LIKELIHOOD FROM INCOMPLETE DATA VIA EM ALGORITHM
    DEMPSTER, AP
    LAIRD, NM
    RUBIN, DB
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-METHODOLOGICAL, 1977, 39 (01): : 1 - 38
  • [7] DAVID: Database for annotation, visualization, and integrated discovery
    Dennis, G
    Sherman, BT
    Hosack, DA
    Yang, J
    Gao, W
    Lane, HC
    Lempicki, RA
    [J]. GENOME BIOLOGY, 2003, 4 (09)
  • [8] Everitt B. S, 2001, APPL MULTIVARIATE DA
  • [9] Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma:: biologic markers of tumour morphology and clinical outcome
    Fangusaro, JR
    Jiang, Y
    Holloway, MP
    Caldas, H
    Singh, V
    Boué, DR
    Hayes, J
    Altura, RA
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (02) : 359 - 365
  • [10] Clustering objects on subsets of attributes
    Friedman, JH
    Meulman, JJ
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2004, 66 : 815 - 839